Neck News and Research

RSS

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first patient has been dosed in a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer coordinated by the Brown University Oncology Research Group (BrUOG).

22 Apr 2013

IMRT reduces feelings of dry mouth in patients with head and neck cancers

Geneva, Switzerland: Researchers have shown for the first time that it is possible to reduce the distressing symptoms of dry mouth in patients treated with radiotherapy for head and neck cancers if the radiation dose to a salivary gland (called the submandibular gland) on the opposite side to the tumour is kept to the minimum.

22 Apr 2013

Obstructive salivary gland disease treatment: an interview with Thomas Cherry, Cook Medical

Everyone is familiar with urinary stones (kidney stones). The same thing can actually happen in your salivary ducts. These types of stones and strictures occur not nearly as frequently as kidney stones but they still occur quite often. The latest data we have seen showed about 1 in 5,000 patients actually have some type of obstructive salivary duct disorder.

From COOK MEDICAL INC. 19 Apr 2013

Researcher explores new way to deliver therapy to brain metastases from primary breast cancer

An Indiana University School of Medicine breast cancer surgeon is pursuing research that will utilize glass, gold, nanotechnology and Greek mythology hoping to vanquish breast cancer that has metastasized to the brain.

19 Apr 2013

Study challenges correlation between bad behaviors in children with hearing implants, language delay

A new study presented today at the 48th Annual American Neurotology Society spring meeting is challenging a long held belief among speech therapists and audiologists that bad behavior in young children with hearing implants is an indicator of device failure and a predictor of poor language development.

15 Apr 2013

Athletes with vocal cord disorder inappropriately treated for exercise-induced asthma

Athletes with a vocal cord disorder that restricts breathing are more likely to be misdiagnosed and inappropriately treated for exercise-induced asthma, according to research presented today at the Triological Society's 116th Annual Meeting.

15 Apr 2013

Navidea presents Phase 3 Lymphoseek study results at international symposium in Athens

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that a presentation of results from its Phase 3 clinical trial of Lymphoseek (technetium 99m tilmanocept) Injection in patients with head and neck squamous cell carcinoma received the 1st Investigator Award at the 2nd InternationaI Symposium on Thoracic and Upper Aerodigestive Malignancies.

15 Apr 2013

UCLA physicians perform new procedure to clear plaque-ridden carotid arteries

Physicians at Ronald Reagan UCLA Medical Center are the first on the West Coast to perform a new, less-invasive procedure that is part of a clinical trial to help clear plaque-ridden carotid arteries.

15 Apr 2013

Study reveals new method to restore grip function in people with tetraplegia

A new method in which a number of operations are performed simultaneously can provide people with tetraplegia with a better grip function and the ability to open their hand. This method also shortens the patient's rehabilitation period by at least three months, reveals a doctoral thesis from the Sahlgrenska Academy, University of Gothenburg, Sweden.

11 Apr 2013

New research finds HPV plays role in lung cancer in some patients

A common virus known to cause cervical and head and neck cancers may also trigger some cases of lung cancer, according to new research presented by Fox Chase Cancer Center at the AACR Annual Meeting 2013 on Wednesday, April 10.

11 Apr 2013

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its Targeted Antibody Payload technology, disclosed for the first time today preclinical data for its EGFR-targeting ADC, IMGN289.

11 Apr 2013

Improvement in application of health information technology needed for better patient care

The break neck pace of genomic discoveries has ushered in a new problem in the delivery of personalized medicine: comprehensive and consistent data reporting that will improve health information technologies for better patient care.

11 Apr 2013

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors.

10 Apr 2013

CYP1B1 protein prevents head and neck cancers, say researchers

Head and neck cancers typically begin in squamous cells that line moist surfaces inside the mouth, nose and throat. Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most common type of cancer in the United States, and it is sometimes preceded by the appearance of changes inside the oral cavity called precancerous lesions.

10 Apr 2013

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.

10 Apr 2013

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

A molecular signature index technology that can lead to better radiation therapy decisions for patients with cancer is being developed into a reliable radiosensitivity test by CvergenX, Inc., an advanced cancer diagnostics company.

10 Apr 2013

Elekta's Versa HD system accelerates radiation delivery to new levels

Featuring a revolutionary combination of speed and accuracy, Elekta's new Versa HD system will help clinicians at The Christie NHS Foundation Trust (Withington, Manchester) maximize the precision of therapeutic beams on the tumor target, while also accelerating radiation delivery to new levels.

From Elekta 10 Apr 2013

Findings could help develop new ways to predict risks of tobacco-associated cancers

Believe it or not, while researchers have explored which genes are mutated in each type of tobacco-associated cancer, until now no one had thought to look across these types for common genes that might predict patient outcomes. Results presented at the AACR Annual Meeting 2013 show that in lung and bladder cancers, genes related to the regulation of the cell cycle are associated with poor patient outcomes.

10 Apr 2013

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.

9 Apr 2013

KYTHERA Biopharmaceuticals presents Phase IIIb study results of ATX-101

KYTHERA Biopharmaceuticals, Inc. today announced positive interim results from a Phase IIIb, multicenter, open-label study (ATX-101-11-26) of ATX-101 during the "Innovations and Renewals" session of the 11th Anti-Aging Medicine World Congress, April 4-6, Monte Carlo, Monaco.

8 Apr 2013

Neck News and Research

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

IMRT reduces feelings of dry mouth in patients with head and neck cancers

Obstructive salivary gland disease treatment: an interview with Thomas Cherry, Cook Medical

Researcher explores new way to deliver therapy to brain metastases from primary breast cancer

Study challenges correlation between bad behaviors in children with hearing implants, language delay

Athletes with vocal cord disorder inappropriately treated for exercise-induced asthma

Navidea presents Phase 3 Lymphoseek study results at international symposium in Athens

UCLA physicians perform new procedure to clear plaque-ridden carotid arteries

Study reveals new method to restore grip function in people with tetraplegia

New research finds HPV plays role in lung cancer in some patients

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

Improvement in application of health information technology needed for better patient care

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

CYP1B1 protein prevents head and neck cancers, say researchers

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

Elekta's Versa HD system accelerates radiation delivery to new levels

Findings could help develop new ways to predict risks of tobacco-associated cancers

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

KYTHERA Biopharmaceuticals presents Phase IIIb study results of ATX-101

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News